Anavex Life Sciences (AVXL) Shares Outstanding (2012 - 2025)

Anavex Life Sciences (AVXL) has 16 years of Shares Outstanding (Entity) data on file, last reported at $92.7 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Entity) rose 9.04% year-over-year to $92.7 million; the trailing twelve-month figure through Dec 2025 stood at $92.7 million (up 9.04% YoY), and the FY2025 full-year result was $86.7 million, up 2.21% from the prior year.
• Shares Outstanding (Entity) advanced to $92.7 million in Q4 2025, from $86.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $92.7 million in Q4 2025 to a low of $70.0 million in Q1 2021.
• A 5-year average of $81.1 million and a median of $81.7 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) advanced 25.08% in 2021 and gained 0.73% in 2025, its largest moves.
• Tracing AVXL's Shares Outstanding (Entity) over 5 years: stood at $76.2 million in 2021, then grew by 2.46% to $78.0 million in 2022, then grew by 5.2% to $82.1 million in 2023, then increased by 3.53% to $85.0 million in 2024, then gained by 9.04% to $92.7 million in 2025.
• Business Quant data shows AVXL's Shares Outstanding (Entity) at $92.7 million in Q4 2025, $86.7 million in Q3 2025, and $85.4 million in Q2 2025.